Drug details:
Classification: Indoles; Indoles and derivatives; Organoheterocyclic compounds; Organic compounds;

Curated SMILES: C1C=CC(C(NC2C=CC=C3C([Se]C4C=CC=CC=4)=CNC=23)=O)=CC=1

Evidence for compound's anti-virulence activity:

Staphylococcus
Related VF: β-hemolysin
Target: Not determined
Drug effect: Inhibits biofilm formation and the hemolytic activity and staphyloxanthin synthesis.
Max phase: Preclinical (in vivo)
Publications:
Rao L, et al., 2021. Small-Molecule Compound SYG-180-2-2 to Effectively Prevent the Biofilm Formation of Methicillin-Resistant Staphylococcus aureus. Front Microbiol 12:770657.
Rao L, et al., 2022. Small-molecule compound SYG-180-2-2 attenuates Staphylococcus aureus virulence by inhibiting hemolysin and staphyloxanthin production. Front Cell Infect Microbiol 12:1008289.